A Prospective Randomized Trial of High Dose Versus Standard Dose Stereotactic Radiotherapy for Pain Control in Patients With Bone Metastases

Bone Metastases Clinical Trial

Official title:

A Prospective Randomized Trial of High Dose Versus Standard Dose Stereotactic Radiotherapy for Pain Control in Patients With Bone Metastases

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04063254
• Other study ID #: 201906063RINB
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: August 30, 2019
• Est. completion date: August 30, 2021

Study information

• Verified date: August 2019
• Source: National Taiwan University Hospital
• Contact: Yun Chiang
• Phone: 0223123456
• Email: chiangyun[@]ntuh.gov.tw
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In the present study, we will prospectively evaluate the pain response and treatment failure rate to determine the most favorable radiation dose in single fraction stereotactic radiotherapy using the modern highly conformal technique for bone metastases. Our findings should be able to provide evidence-based recommendation to support the utilization of single fraction radiotherapy for value-based oncology practice.

Description:

Primary objective To evaluate dose regimen for pain control in terms of rate of treatment failure, defined as the first occurrence of any of the following events, at 3 months

1. Worsening in the worst pain score by at least 3 by brief pain inventory survey

2. ≥ 50% increase in dose of opioid/narcotic medication

3. Development of pathologic fracture or cord/nerve compression indicative of surgical intervention

4. Unequivocal radiographic disease progression

Secondary objectives

1. Compare pain response/control at the treated site(s) between the two treatment regimens by brief pain inventory survey

2. Assess health-related quality of life for palliative cancer care patients (EORTC QLQ-C15-PAL & EORTC-BM22 Mandarin Taiwan)

3. Evaluate the analgescis use after irradiation

4. Evaluate acute and late adverse events associated with irradiation according to CTCAE criteria

5. To evaluate the local control of the treated index site(s)

6. To evaluate the patterns of failure

7. To evlaute overall survival

8. To evaluate the rate of re-irradiation, salvage surgery, interventional procedure, and MR-guided high intensity focused ultrasound at the treated site(s)

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 302
• Est. completion date: August 30, 2021
• Est. primary completion date: August 30, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

1. Patients with a histologic diagnosis of non-hematopoietic malignancy

2. Radiographic evidence of bone metastases

3. Patient with pain or dysathesia on a pain score of at least 2 by brief pain inventory survey

4. Multiple osseous sites are eligible with a maximum of three separate sites irradiated concurrently

5. Patients do not have prior radiotherapy or radiosurgery to the index site(s)

6. Age = 20 years

7. Karnofsky performance status (KPS) = 50%.

8. Life expectancy of = 3 months

9. Women of childbearing potential and male participants must practice adequate contraception

10. Patients must be able to comply with the study protocol, pain assessment, quality of life survey, and follow-up schedules and provide study-specific informed consent

Exclusion Criteria:

1. Patients with radiographic impending or pathological fracture, or malignant epidural cord compression at the index site(s) indicative of upfront surgery

2. Prior radiotherapy or radiosurgery to the index site(s)

3. Previously treated with radioactive isotope (e.g. Ra-223) within 30 days of registration

4. Inability to cooperate treatment procedure

5. Severe, active comorbidities which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and adverse events of the protocol, or limit compliance with study requirements, defined as follows:

1. Uncontrolled active infection requiring intravenous antibiotics at the time of registration

2. Transmural myocardial infarction = 6 months prior to registration

3. Unstable angina or congestive heart failure requiring hospitalization = 6 months prior to registration

4. Life-threatening uncontrolled clinically significant cardiac arrhythmias

5. Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects

6. Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration

7. Uncontrolled psychiatric disorder

6. Will receive any other investigational agent or chemotherapy during treatment

7. Women of childbearing potential and male participants who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the radiation treatment involved in this study may be significantly teratogenic

8. Pregnant or breast-feeding women

Related Conditions & MeSH terms

• Bone Marrow Diseases
• Bone Metastases
• Bone Neoplasms
• Neoplasm Metastasis
• Radiotherapy Side Effect

Intervention

Radiation:
• Stereotactic Radiotherapy
High Dose (Arm A): Stereotactic radiotherapy with 12 or 16 Gy in single fraction using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc). Standard-dose (Arm B): Stereotactic radiotherapy with 8 or 10 Gy in single fraction using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc).

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
National Taiwan University Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Effects of treatment	To evaluate dose regimen for pain control in terms of rate of treatment failure, defined as the first occurrence of any of the following events	3 months